Xin Lang Cai Jing·2025-09-02 01:23Group 1 - On September 1, Junshi Biosciences experienced a stock price increase of 4.71% with a trading volume of 1.08 billion yuan [1] - The financing data for Junshi Biosciences on the same day showed a net financing purchase of 7.418 million yuan, with a total financing balance of 1.3 billion yuan, which is 3.57% of its market capitalization [1] - The company's short selling data indicated a short selling balance of 9.655 million yuan, exceeding the 80th percentile of the past year, indicating a high level of short interest [1] Group 2 - As of June 30, Junshi Biosciences had 31,200 shareholders, an increase of 5.88% from the previous period, while the average number of circulating shares per person decreased by 5.56% to 24,543 shares [2] - For the first half of 2025, Junshi Biosciences reported a revenue of 1.168 billion yuan, representing a year-on-year growth of 48.64%, while the net profit attributable to shareholders was -413 million yuan, an increase of 36.01% year-on-year [2] - Among the top ten circulating shareholders, Huaxia SSE STAR 50 ETF held 29.7167 million shares, a decrease of 536,700 shares, while E Fund SSE STAR 50 ETF increased its holdings by 630,000 shares to 22.2132 million shares [2]